HCV: SOF/VEL yields 95% clearance rate in dialysis patients

  • Borgia SM & al.
  • J Hepatol
  • 10 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pangenotypic sofosbuvir/velpatasvir (SOF/VEL, Epclusa) safely achieves a 95% HCV clearance rate among patients undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD).

Why this matters

  • The prescribing information does not offer dosing recommendations for patients with estimated glomerular filtration rate (eGFR, in mL/minute/1.73 m2)

Study design

  • Multinational phase 2 open-label study of 59 patients (mean age, 60 years; 60% male) with HCV genotypes (GT) 1-6 undergoing hemodialysis (92%, mean, 7 years) or peritoneal dialysis and receiving 12 weeks of standard-dose SOF/VEL.
  • 78% were treatment-naive; 29% had cirrhosis.
  • Sustained virologic response was measured at 12 weeks posttreatment (SVR12).
  • Funding: Gilead Sciences.

Key results

  • GT1 was most common (42%: 1a, 25%; 1b, 19%), followed by GT3 (32%), GT2 (12%), GT4 (7%), and GT6 (3%); GT was undetermined in 9%.
  • SVR12 rate was 95% (56/59; 95% CI, 86%-99%).
  • Of 3 non-SVR12 patients, 2 relapsed at week 4 posttreatment (1 nonadherent, 1 with treatment-experienced HCV-3a); 1 patient committed suicide.
  • SOF, SOF metabolite, and VEL exposures were 81%, 1719%, and 41% higher, respectively, than that observed with normal renal function.
  • Adverse events (incidence >10%): headache (17%), fatigue/nausea/vomiting (14% each); no serious events were related to SOF/VEL.

Limitations

  • Single-arm design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit